Multiple Myeloma

P=N/A, N=1, Active, not recruiting, Pfizer | Not yet recruiting --> Active, not recruiting | N=30 --> 1

P1, N=46, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2030 --> May 2028 | Trial primary completion date: Feb 2030 --> May 2028

P=N/A, N=180, Recruiting, University of Nebraska | Phase classification: P2 --> P=N/A

In summary, PCIF1 activated USP5/BRD4 axis to promote MM cell survival and immune escape, suggesting that targeting PCIF1 may represent a novel therapeutic strategy for MM.

In murine xenotransplant myeloma models, giving APRIL during the first week after infusion of BCMA CAR T-cells increased IFNγ-positive CAR T-cells in the tumor tissues, and enhanced the anti-tumor effect of CAR T-cell. In conclusion, APRIL counteracted the actions of sBCMA in BCMA CAR T-cell-mediated binding and killing of myeloma cells which might contribute to the efficacy of BCMA CAR T-cell therapies.

This case highlights anterior orbital involvement presenting as apparent involutional lower eyelid fat herniation, a potential diagnostic pitfall. Awareness of this presentation is important when evaluating new eyelid or orbital findings in patients with a history of systemic malignancy.

P2, N=20, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting

P=N/A, N=12, Terminated, Mayo Clinic | N=20 --> 12 | Trial completion date: Sep 2026 --> Jun 2026 | Recruiting --> Terminated | Trial primary completion date: Sep 2026 --> Jun 2026; Limited funding, slow accrual

P1, N=27, Not yet recruiting, Luminary Therapeutics

P1, N=3, Completed, Elvira Umyarova | Active, not recruiting --> Completed

P1, N=36, Active, not recruiting, GlaxoSmithKline | Trial completion date: Dec 2025 --> Mar 2027

P2, N=60, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2031 --> Dec 2032 | Trial primary completion date: Dec 2026 --> Dec 2027